Bal Pharma Limited (NSE:BALPHARMA) — Market Cap & Net Worth
Market Cap & Net Worth: Bal Pharma Limited (BALPHARMA)
Bal Pharma Limited (NSE:BALPHARMA) has a market capitalization of $13.12 Million (Rs1.21 Billion) as of May 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #26203 globally and #1467 in its home market, demonstrating a -2.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bal Pharma Limited's stock price Rs76.21 by its total outstanding shares 15920872 (15.92 Million). Analyse BALPHARMA operating cash flow to see how efficiently the company converts income to cash.
Bal Pharma Limited Market Cap History: 2015 to 2026
Bal Pharma Limited's market capitalization history from 2015 to 2026. Data shows growth from $18.95 Million to $13.12 Million (0.13% CAGR).
Bal Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bal Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Bal Pharma Limited's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.17x
Bal Pharma Limited's market cap is 0.17 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $14.42 Million | $1.98 Billion | $14.05 Million | 0.01x | 1.03x |
| 2017 | $17.75 Million | $2.29 Billion | $19.86 Million | 0.01x | 0.89x |
| 2018 | $12.81 Million | $2.09 Billion | $27.82 Million | 0.01x | 0.46x |
| 2019 | $6.82 Million | $2.25 Billion | $37.88 Million | 0.00x | 0.18x |
| 2020 | $9.33 Million | $1.71 Billion | -$122.18 Million | 0.01x | N/A |
| 2021 | $17.70 Million | $2.47 Billion | $47.42 Million | 0.01x | 0.37x |
| 2022 | $15.39 Million | $2.81 Billion | $56.12 Million | 0.01x | 0.27x |
| 2023 | $17.07 Million | $3.04 Billion | $25.72 Million | 0.01x | 0.66x |
| 2024 | $21.11 Million | $3.39 Billion | $73.92 Million | 0.01x | 0.29x |
| 2025 | $12.62 Million | $3.03 Billion | $72.15 Million | 0.00x | 0.17x |
Competitor Companies of BALPHARMA by Market Capitalization
Companies near Bal Pharma Limited in the global market cap rankings as of May 4, 2026.
Key companies related to Bal Pharma Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Bal Pharma Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Bal Pharma Limited's market cap moved from $18.95 Million to $ 13.12 Million, with a yearly change of 0.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs13.12 Million | +3.94% |
| 2025 | Rs12.62 Million | -40.21% |
| 2024 | Rs21.11 Million | +23.66% |
| 2023 | Rs17.07 Million | +10.92% |
| 2022 | Rs15.39 Million | -13.02% |
| 2021 | Rs17.70 Million | +89.63% |
| 2020 | Rs9.33 Million | +36.77% |
| 2019 | Rs6.82 Million | -46.74% |
| 2018 | Rs12.81 Million | -27.84% |
| 2017 | Rs17.75 Million | +23.07% |
| 2016 | Rs14.42 Million | -23.88% |
| 2015 | Rs18.95 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Bal Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.12 Million USD |
| MoneyControl | $13.12 Million USD |
| MarketWatch | $13.12 Million USD |
| marketcap.company | $13.12 Million USD |
| Reuters | $13.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bal Pharma Limited
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Az… Read more